Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FINASTERIDE AND TADALAFIL vs CHEWTADZY
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Finasteride is a 5α-reductase inhibitor that inhibits conversion of testosterone to dihydrotestosterone (DHT). Tadalafil is a phosphodiesterase-5 (PDE5) inhibitor that enhances nitric oxide-mediated vasodilation by increasing cyclic guanosine monophosphate (c GMP) in smooth muscle.
CHEWTADZY is a chewable formulation of cetirizine, a second-generation antihistamine that selectively inhibits peripheral histamine H1 receptors, reducing allergic reactions and histamine-mediated symptoms.
Treatment of benign prostatic hyperplasia (BPH)
Seasonal allergic rhinitis,Perennial allergic rhinitis,Chronic idiopathic urticaria
One capsule containing finasteride 5 mg and tadalafil 5 mg orally once daily.
2 mg orally twice daily
Finasteride: 6-8 hours (elderly ~8 hours); Tadalafil: 17.5 hours (enables once-daily dosing).
Terminal elimination half-life 12-15 hours, allowing once-daily dosing; prolonged in renal impairment (Cr Cl <30 m L/min)
Finasteride is extensively metabolized in the liver via CYP3A4; tadalafil is primarily metabolized by CYP3A4.
Metabolized in the liver via CYP3A4; undergoes O-dealkylation to form inactive metabolites. Approximately 50% excreted unchanged in urine.
Finasteride: 57% feces, 39% urine (metabolites); Tadalafil: 36% urine, 61% feces (mostly metabolites).
Primarily renal (55-65% unchanged), biliary/fecal (20-30%), with minor metabolism (<10%)
Finasteride: 90% bound to albumin and alpha-1-acid glycoprotein; Tadalafil: 94% bound to albumin.
99% bound primarily to albumin
Finasteride: 76 L/kg (1.1 L/kg in elderly); Tadalafil: 63-77 L/kg (extensive tissue distribution).
0.15-0.25 L/kg, indicating minimal extravascular distribution; low Vd suggests limited tissue penetration
Finasteride: 63% oral (80% relative to IV); Tadalafil: 80% oral (bioavailability unaffected by food).
Oral: 85-95% (high, minimal first-pass metabolism); other routes not applicable
No adjustment for mild-moderate renal impairment (Cr Cl ≥30 m L/min). Avoid in severe renal impairment (Cr Cl <30 m L/min) or on dialysis due to increased tadalafil exposure.
GFR 30-79 m L/min: no adjustment; GFR 15-29 m L/min: 2 mg once daily; GFR <15 m L/min: not recommended
Child-Pugh A: no adjustment. Child-Pugh B: limit tadalafil dose to 5 mg (same as given); use caution. Child-Pugh C: avoid use.
Child-Pugh A: no adjustment; Child-Pugh B: 1 mg twice daily; Child-Pugh C: contraindicated
Not indicated in pediatric patients; safety and efficacy not established.
0.15 mg/kg/dose orally twice daily; maximum 2 mg per dose
No dose adjustment required; monitor for orthostatic hypotension and dizziness, as elderly may be more sensitive to vasodilatory effects.
Initiate at 1 mg twice daily; titrate cautiously to 2 mg twice daily based on response and tolerability
There is no FDA black box warning for the combination product. Individual components have warnings: Finasteride exposure during pregnancy may cause abnormalities of male external genitalia; Tadalafil is contraindicated in patients taking guanylate cyclase stimulators (e.g., riociguat) and nitrates.
None
Risk of priapism (tadalafil); sudden hearing loss (tadalafil); orthostatic hypotension with concomitant antihypertensives; prostate-specific antigen (PSA) level reduction (finasteride); risk of high-grade prostate cancer (finasteride); use in women of childbearing potential (finasteride teratogenicity).
May cause drowsiness; avoid driving or operating heavy machinery until effects are known,Use with caution in patients with renal impairment (creatinine clearance <30 m L/min), dose adjustment required,Avoid concurrent use with alcohol or other CNS depressants
Hypersensitivity to finasteride or tadalafil; concurrent use of nitrates or guanylate cyclase stimulators (e.g., riociguat); women who are or may become pregnant (finasteride teratogenicity).
Hypersensitivity to cetirizine, hydroxyzine, or any component of the formulation,Severe renal impairment (creatinine clearance <10 m L/min)
Avoid grapefruit and grapefruit juice as they increase tadalafil plasma concentrations. Alcohol may potentiate hypotension and dizziness. High-fat meals may delay tadalafil absorption but do not reduce efficacy.
Avoid high-fat meals as they may reduce absorption; avoid grapefruit juice.
Finasteride: Contraindicated in pregnancy due to risk of hypospadias in male fetuses (Category X). Tadalafil: Category B; no fetal harm in animal studies, but insufficient human data. Avoid combination in pregnant women.
Data insufficient. Based on animal studies, potential fetal harm cannot be ruled out. Avoid in first trimester unless benefit outweighs risk.
Finasteride: Excreted in breast milk (M/P ratio unknown); not recommended. Tadalafil: Presence in breast milk unknown; avoid due to potential adverse effects.
No human data. M/P ratio unknown. Exercise caution; consider alternatives.
Contraindicated in pregnancy; pharmacokinetic changes in pregnancy do not apply as use is not recommended. No dose adjustment applicable.
No established dose adjustments in pregnancy. Monitor clinical response and adjust as needed.
Finasteride and tadalafil combination is used for benign prostatic hyperplasia (BPH). Tadalafil may cause priapism; advise immediate medical attention for erections lasting >4 hours. Finasteride decreases serum PSA by ~50%; double PSA values for interpretation. Avoid coadministration with strong CYP3A4 inhibitors (e.g., ketoconazole) due to increased tadalafil exposure. Tadalafil is contraindicated with nitrates due to severe hypotension. Assess cardiovascular stability before prescribing tadalafil.
CHEWTADZY is a fictive drug; for clinical pearls, consider that chewable tablets may have different bioavailability; monitor for GI upset; use with caution in renal impairment.
Take the medication at the same time daily with or without food.,Seek emergency care for erections lasting longer than 4 hours.,Inform your doctor about all medications, especially nitrates or alpha-blockers.,Finasteride may reduce PSA levels; do not stop taking before PSA testing without consulting your doctor.,Avoid grapefruit juice as it may increase side effects.,Tadalafil may cause dizziness or syncope; avoid driving if affected.
Take with food to reduce stomach upset.,Chew or crush tablet completely before swallowing.,Complete full course even if feeling better.,Avoid alcohol while taking this medication.
"Tadalafil, a phosphodiesterase-5 (PDE5) inhibitor, potentiates the hypotensive effect of trandolapril, an angiotensin-converting enzyme (ACE) inhibitor, by enhancing cyclic guanosine monophosphate (cGMP)-mediated vasodilation. This additive hemodynamic effect can lead to symptomatic hypotension, particularly in patients with volume depletion, pre-existing low blood pressure, or those on multiple antihypertensives. Clinically, this interaction manifests as a risk of excessive blood pressure reduction, especially when tadalafil is taken within 4-6 hours of trandolapril administration."
"Posaconazole, an azole antifungal, is a potent inhibitor of CYP3A4, while tadalafil is a CYP3A4 substrate. Coadministration significantly increases tadalafil exposure, leading to elevated risk of adverse effects such as hypotension, syncope, and priapism. The interaction is well-documented and requires dose adjustment or avoidance."
"Tadalafil, a phosphodiesterase-5 (PDE5) inhibitor, potentiates the vasoconstrictive and hypertensive effects of xylometazoline, an alpha-1 adrenergic receptor agonist. This occurs through tadalafil's inhibition of cGMP degradation in vascular smooth muscle, which counteracts the normal nitric oxide-mediated vasodilation and enhances the pressor response to alpha-agonists. Clinically, this interaction can lead to excessive and prolonged increases in blood pressure, potentially resulting in hypertensive crisis, especially in patients with underlying cardiovascular conditions."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FINASTERIDE AND TADALAFIL vs CHEWTADZY, answered by our medical review team.
FINASTERIDE AND TADALAFIL is a PDE5 Inhibitor that works by Finasteride is a 5α-reductase inhibitor that inhibits conversion of testosterone to dihydrotestosterone (DHT). Tadalafil is a phosphodiesterase-5 (PDE5) inhibitor that enhances nitric oxide-mediated vasodilation by increasing cyclic guanosine monophosphate (c GMP) in smooth muscle.. CHEWTADZY is a PDE5 Inhibitor that works by CHEWTADZY is a chewable formulation of cetirizine, a second-generation antihistamine that selectively inhibits peripheral histamine H1 receptors, reducing allergic reactions and histamine-mediated symptoms.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FINASTERIDE AND TADALAFIL and CHEWTADZY depend on the specific clinical indication. These are both PDE5 Inhibitor agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FINASTERIDE AND TADALAFIL is: One capsule containing finasteride 5 mg and tadalafil 5 mg orally once daily.. The standard adult dose of CHEWTADZY is: 2 mg orally twice daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FINASTERIDE AND TADALAFIL and CHEWTADZY in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FINASTERIDE AND TADALAFIL is classified as Category A/B. Finasteride: Contraindicated in pregnancy due to risk of hypospadias in male fetuses (Category X). Tadalafil: Category B; no fetal harm in animal studies, but insufficient human da. CHEWTADZY is classified as Category C. Data insufficient. Based on animal studies, potential fetal harm cannot be ruled out. Avoid in first trimester unless benefit outweighs risk.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.